NPCE RSI Chart
Last 7 days
-4.8%
Last 30 days
-41.2%
Last 90 days
-50.8%
Trailing 12 Months
90.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 69.1M | 0 | 0 | 0 |
2023 | 48.6M | 54.9M | 60.2M | 65.4M |
2022 | 45.3M | 42.9M | 43.7M | 45.5M |
2021 | 42.4M | 47.4M | 44.9M | 45.2M |
2020 | 0 | 0 | 0 | 41.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 03, 2024 | orbimed advisors llc | sold | -65,576 | 14.03 | -4,674 | - |
May 02, 2024 | orbimed advisors llc | sold | -123,876 | 14.01 | -8,842 | - |
May 01, 2024 | orbimed advisors llc | sold | -219,974 | 14.02 | -15,690 | - |
Apr 24, 2024 | orbimed advisors llc | sold | -25,040 | 14.06 | -1,781 | - |
Apr 23, 2024 | orbimed advisors llc | sold | -311,393 | 14.29 | -21,791 | - |
Apr 22, 2024 | orbimed advisors llc | sold | -345,756 | 14.05 | -24,609 | - |
Apr 19, 2024 | orbimed advisors llc | sold | -255,907 | 14.02 | -18,253 | - |
Apr 18, 2024 | orbimed advisors llc | sold | -36,879 | 14.06 | -2,623 | - |
Apr 17, 2024 | orbimed advisors llc | sold | -4,245 | 14.15 | -300 | - |
Apr 16, 2024 | orbimed advisors llc | sold | -197,107 | 14.01 | -14,069 | - |
Which funds bought or sold NPCE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 95.57 | 570,937 | 950,572 | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | -1,000 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -57.04 | -148,021 | 180,919 | -% |
May 15, 2024 | MORGAN STANLEY | added | 0.95 | 7,418,590 | 32,788,600 | -% |
May 15, 2024 | STATE STREET CORP | added | 11.69 | 147,864 | 491,713 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -66.12 | -140,427 | 107,580 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 1,845,930 | 1,845,930 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 1,393 | 47,074 | 49,672 | -% |
May 15, 2024 | ORBIMED ADVISORS LLC | unchanged | - | 11,571,500 | 52,852,400 | 0.97% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -2.06 | 88,731 | 438,240 | 0.01% |
Unveiling NeuroPace, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NeuroPace, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
NeuroPace, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | 0.6% | 18.00 | 18.00 | 16.00 | 17.00 | 14.00 | 13.00 | 11.00 | 10.00 | 11.00 | 11.00 | 10.00 | 13.00 | 11.00 | 11.00 | 13.00 | 8.00 | 10.00 |
Gross Profit | -1.5% | 13.00 | 14.00 | 12.00 | 12.00 | 10.00 | 9.00 | 8.00 | 7.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 10.00 | 5.00 | 7.00 |
Operating Expenses | 12.3% | 21.00 | 19.00 | 18.00 | 20.00 | 19.00 | 19.00 | 18.00 | 18.00 | 18.00 | 17.00 | 14.00 | 14.00 | 12.00 | 11.00 | 11.00 | 9.00 | 13.00 |
S&GA Expenses | 14.3% | 15.00 | 13.00 | 13.00 | 14.00 | 13.00 | 14.00 | 13.00 | 13.00 | 12.00 | 12.00 | 9.00 | 10.00 | 8.00 | 7.00 | 7.00 | 6.00 | 8.00 |
R&D Expenses | 7.6% | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 5.00 |
Interest Expenses | 1.0% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 4.00 | 3.00 |
Net Income | -44.0% | -8.93 | -6.20 | -7.26 | -9.12 | -10.37 | -11.15 | -11.78 | -12.69 | -11.46 | -10.69 | -8.08 | -8.49 | -8.81 | -4.62 | -4.13 | -8.79 | -6.74 |
Net Income Margin | 9.5% | -0.46* | -0.50* | -0.63* | -0.77* | -0.95* | -1.03* | -1.07* | -1.00* | -0.85* | -0.80* | -0.67* | -0.55* | - | - | - | - | - |
Free Cashflow | -126.3% | -7.63 | -3.37 | -2.27 | -4.40 | -9.83 | -8.00 | -6.93 | -10.86 | -11.71 | -8.35 | -4.63 | -6.07 | - | - | - | - | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -8.2% | 99.00 | 108 | 99.00 | 102 | 106 | 114 | 120 | 119 | 129 | 134 | 141 | 147 | 50.00 | 56.00 |
Current Assets | -9.1% | 84.00 | 93.00 | 84.00 | 87.00 | 90.00 | 98.00 | 104 | 112 | 122 | 133 | 140 | 146 | 47.00 | 55.00 |
Cash Equivalents | -27.3% | 13.00 | 18.00 | 10.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 7.00 | 19.00 | 27.00 | 31.00 | 14.00 | 27.00 |
Inventory | 1.8% | 11.00 | 11.00 | 10.00 | 10.00 | 11.00 | 10.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 |
Net PPE | 4.5% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 |
Liabilities | -2.9% | 85.00 | 87.00 | 83.00 | 81.00 | 79.00 | 79.00 | 77.00 | 66.00 | 66.00 | 60.00 | 60.00 | 58.00 | 65.00 | 62.00 |
Current Liabilities | -19.2% | 13.00 | 16.00 | 13.00 | 12.00 | 10.00 | 11.00 | 9.00 | 11.00 | 12.00 | 9.00 | 9.00 | 8.00 | 11.00 | 10.00 |
Long Term Debt | 1.9% | 58.00 | 57.00 | 56.00 | 55.00 | 54.00 | 53.00 | 52.00 | 51.00 | 50.00 | 50.00 | 50.00 | 49.00 | 50.00 | 51.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00 | 2.00 |
LT Debt, Non Current | -100.0% | - | 57.00 | 56.00 | 55.00 | 54.00 | 53.00 | 52.00 | 51.00 | 50.00 | 50.00 | 50.00 | 49.00 | 50.00 | 51.00 |
Shareholder's Equity | -30.6% | 14.00 | 21.00 | 16.00 | 21.00 | 27.00 | 35.00 | 43.00 | 53.00 | 63.00 | 74.00 | 82.00 | 89.00 | - | - |
Retained Earnings | -1.8% | -512 | -503 | -497 | -490 | -481 | -470 | -459 | -447 | -435 | -423 | -413 | -405 | -396 | -387 |
Additional Paid-In Capital | 0.5% | 527 | 524 | 514 | 512 | 509 | 507 | 504 | 502 | 499 | 498 | 495 | 494 | 240 | 240 |
Shares Outstanding | 3.2% | 29.00 | 28.00 | 26.00 | 26.00 | 25.00 | 25.00 | 25.00 | 25.00 | 24.00 | 24.00 | 24.00 | 18.00 | - | - |
Float | - | - | - | - | 66.00 | - | - | - | 50.00 | - | - | - | 198 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -125.3% | -7,528 | -3,341 | -2,260 | -4,402 | -9,698 | -7,900 | -6,900 | -10,700 | -11,400 | -8,200 | -4,450 | -6,050 | -5,900 | -6,400 | -5,400 | -3,300 | -6,500 |
Share Based Compensation | 7.8% | 2,540 | 2,357 | 2,421 | 2,655 | 2,125 | 2,076 | 2,182 | 2,603 | 1,488 | 1,876 | 1,107 | 1,103 | 202 | 487 | 301 | 290 | 301 |
Cashflow From Investing | -30.9% | 2,396 | 3,468 | 4,191 | 5,300 | 10,068 | 8,898 | 6,969 | 8,236 | -306 | -154 | -190 | -80,017 | -5,035 | -10,046 | -250 | - | -471 |
Cashflow From Financing | -99.1% | 72.00 | 8,214 | -27.00 | 195 | -255 | -138 | -8.00 | 635 | 1.00 | 911 | - | 103,193 | -1,578 | -279 | 38,815 | 3,953 | 12,520 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 18,124 | $ 14,472 |
Cost of goods sold | 4,781 | 4,100 |
Gross profit | 13,343 | 10,372 |
Operating expenses | ||
Research and development | 5,784 | 5,263 |
Selling, general and administrative | 15,104 | 13,428 |
Total operating expenses | 20,888 | 18,691 |
Loss from operations | (7,545) | (8,319) |
Interest income | 827 | 726 |
Interest expense | (2,258) | (1,965) |
Other income (expense), net | 51 | (817) |
Net loss | (8,925) | (10,375) |
Comprehensive loss | $ (8,925) | $ (10,375) |
Net loss per share attributable to common stockholders, basic (in dollars per share) | $ (0.32) | $ (0.41) |
Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (0.32) | $ (0.41) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 28,285,176 | 25,097,262 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 28,285,176 | 25,097,262 |
Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 12,998 | $ 18,058 |
Short-term investments | 45,947 | 48,396 |
Accounts receivable | 11,631 | 12,314 |
Inventory | 11,416 | 11,214 |
Prepaid expenses and other current assets | 2,262 | 2,737 |
Total current assets | 84,254 | 92,719 |
Property and equipment, net | 1,048 | 1,003 |
Operating lease right-of-use asset | 13,027 | 13,405 |
Restricted cash | 122 | 122 |
Deferred offering costs | 387 | 387 |
Other assets | 15 | 15 |
Total assets | 98,853 | 107,651 |
Current liabilities | ||
Accounts payable | 3,268 | 2,332 |
Accrued liabilities | 7,290 | 11,180 |
Operating lease liability | 1,683 | 1,627 |
Deferred revenue | 869 | 1,090 |
Total current liabilities | 13,110 | 16,229 |
Long-term debt | 58,039 | 56,954 |
Operating lease liability, net of current portion | 13,363 | 13,814 |
Total liabilities | 84,512 | 86,997 |
Commitments and contingencies (Note 5) | ||
Stockholders’ equity | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 28,717,452 and 27,823,465 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 29 | 28 |
Additional paid-in capital | 527,046 | 524,435 |
Accumulated deficit | (512,734) | (503,809) |
Total stockholders’ equity | 14,341 | 20,654 |
Total liabilities and stockholders’ equity | $ 98,853 | $ 107,651 |